A consortium of aging research institutions has validated a comprehensive biomarker panel that can predict biological age with 95% accuracy, providing individuals and clinicians with an unprecedented tool for monitoring aging and evaluating anti-aging interventions.
The panel, called AgePrint, combines 14 blood-based biomarkers — including inflammatory markers, metabolic indicators, epigenetic methylation patterns, and telomere length — into a single biological age score. In validation studies involving over 100,000 individuals across diverse populations, the score reliably predicted remaining healthy lifespan and disease risk.
"For the first time, we can precisely measure how fast someone is aging and track whether lifestyle changes or medical interventions are actually making a difference," said Dr. Morgan Levine of Yale University, one of the panel's developers.
The test is now available through select clinical laboratories at a cost of approximately $300. Several insurance companies are evaluating coverage, particularly given the potential for early disease detection and prevention.
Early adopters are using AgePrint to optimize their longevity strategies, testing the effects of various interventions — from exercise and dietary changes to supplements and medications — on their biological age scores. Researchers hope the widespread adoption of biological age testing will accelerate longevity research by providing standardized outcome measures for clinical trials.